Physician profile
David Kim
NPI 1801803101
$8,160.77
in general payments reported to CMS, 2019-2025
17 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $156 · 2021: $559 · 2022: $627 · 2023: $503 · 2024: $5,605 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,400 · Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,400.00 |
| Food and Beverage | $1,192.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $5,400.00 | 2024 | Heplisav-B |
| Abbott Laboratories | $973.38 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Jot Dx, Quartet |
| Novartis Pharmaceuticals Corporation | $478.32 | 2019-2025 | |
| Medtronic, INC. | $305.23 | 2021-2024 | Onyx Frontier |
| Boston Scientific Corporation | $161.19 | 2019-2022 | |
| Biotronik INC. | $126.67 | 2020 | |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Amgen INC. | $122.51 | 2024-2025 | Repatha, Repatha |
| Pfizer INC. | $102.33 | 2020-2025 | |
| Atricure, INC. | $93.50 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $74.34 | 2023 | Camzyos |
| Alnylam Pharmaceuticals INC. | $56.37 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $45.28 | 2021-2023 | Xarelto |
| Angiodynamics, INC. | $29.19 | 2025 | Angiovac |
| Lantheus Medical Imaging, INC. | $27.10 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventice Services, LLC | $25.83 | 2019 | |
| Amarin Pharma, INC. | $14.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.